GEO series
Inhibition of BCL2 family proteins overcomes acquired resistance to standard of care BRAF and MEK inhibitors in a subset of BRAFV600E-mutant melanomas
GSE298507
Homo sapiens
Expression profiling by high throughput sequencing; Genome variation profiling by high throughput sequencing
58 samples
2026/03/30
GPL11154
Summary
Despite recent advances, a significant number of melanoma patients treated with BRAF and MEK targeted therapies (BRAFi/MEKi) or immunotherapies develop progressive disease. Anti-apoptotic BCL family proteins have been shown to promote de novo resistance to a number of therapies, including single-agent BRAF inhibitors in BRAF-mutant melanomas. In this study, in vivo testing of a collection of BRAFi- or BRAFi/MEKi treatment-refractory melanoma patient-derived xenograft (PDX) models showed that combining BCL2 inhibitors (BCL2i, navitoclax or venetoclax) with BRAFi and MEKi surprisingly induced potent regressions of a significant subset of these treatment-refractory PDXs. High basal BCL2 expression correlated with improved sensitivity, while high basal MCL1 predicted resistance to BCL2i combination with BRAFi/MEKi. Studies with MCL1 overexpression functionally validated its role in resistance. Further, combination of BRAFi/MEKi with a MCL1 inhibitor (MCL1i) counteracted the resistance and also decreased MCL1i-associated cardiotoxicity markers.
Download
NCBI GEO page ↗
{# Names what the click gives you. "Open in finder" meant nothing to a
visitor who arrived from a search engine and has never seen the tool. #}
Find more
human RNA-seq datasets →
Similar datasets
- GSE247793 Cell cycle checkpoint proficiency of endometrial cancer cells 42 samples
- GSE310962 EGFR-mutant transformed small cell lung cancer harbors intratumoral heterogeneity targetable with MEK inhibitor combination therapy 8 samples
- GSE301458 Single-cell analysis of human fibrous dysplasia bone reveals a fibrotic transcriptome and somatic, mosaic GNAS R201H/C mutations in endothelial, perivascular, and stromal cells 12 samples
- GSE328275 Single-cell RNA sequencing of CD45+ immune cells across primary tumor, sentinel tumor-draining lymph node, and axillary lymph node in treatment-naive triple-negative breast cancer 28 samples
- GSE341753 Cohesin loading at regulatory elements shapes 3D genome folding during erythropoiesis [RNA-Seq] 12 samples
- GSE316079 SLF2 and SMC5 dysfunction drives HSC aging and predisposes to MDS, defining a new inherited bone marrow failure syndrome [ATAC-seq] 6 samples
- GSE323364 Coordinating catalytic and non-canonical functions of EZH2 sensitizes tumors to CAR-T cell therapy 42 samples
- GSE319969 Spatial and Bulk Transcriptomic Profiling Defines the Molecular Evolution of Cutaneous Squamous Cell Carcinoma and Reveals Stage-Specific Biomarkers of Clinical Relevance [RNA-Seq] 24 samples
Share this dataset
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.